EDC · LiveBook a demo
All studies
Phase 3RecruitingInterventionalNCT07253285

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Efficacy, Safety and Pharmacokinetics of Cagrilintide s.c. 2.4 mg as Monotherapy and in Combination With Semaglutide s.c. 2.4 mg (CagriSema) Once Weekly for Weight Management in Chidren and Adolescents With Overweight or Obesity

  • Overweight
  • Obesity
I want to take partRefer a patient9 sites in India · 121 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
Novo Nordisk A/S
Enrolment target
460
Started
8 January 2026
Main results due (estimated)
20 March 2030
Study ends (estimated)
20 September 2033
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Sites
121 · 9 in India
First posted
28 November 2025
Registry updated
30 September 2026

Sponsor staff involved in the clinical trial is masked according to company standard procedures. The main phase of the study is double blinded and followed by an open label extension phase.

Can you take part?

  • Ages 8 years to 18 years.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: child, adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion criteria:

* Informed consent of parent(s) or legally acceptable representative (LAR) of participant and child assent, as age-appropriate, obtained before any study related activities. Study related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
* The parent(s) or LAR of the child must sign and date the Informed Consent Form (according to local requirements)
* The child must sign and date the Child Assent Form or provide oral assent (according to local requirements).
* Male or female.
* Aged 8 to less than (\<) 18 years at the time of signing the informed consent.
* Body mass index (BMI), at screening, corresponding to:
* Greater than or equal to (\>=) 95th percentile for children aged 8 to \< 12 years (Tanner stage 1-5)
* \>= 95th percentile or \>= 85th percentile with the presence of at least one obesity-related complication including, but not limited to, type 2 diabetes (T2D), hypertension, dyslipidaemia or obstructive sleep apnoea for adolescents aged 12 to \< 18 years (Tanner stage 2-5).
* Laboratory parameters, as measured by the central lab at screening, within normal sex- and age-specific ranges of total calcium, phosphate, alkaline phosphatase, parathyroid hormone.
* History of at least one unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification programme (diet and exercise counselling) for at least 3 months.
* Body weight greater than (\>) 45 kilograms (kg) at screening.

For participants with T2D at screening the following inclusion criteria also apply

* Glycated haemoglobin (HbA1c) less than or equal to (\<=)10.0 percent (%) (86 millimoles per mole \[mmol/mol\]) as measured by central laboratory at screening.
* Treatment with lifestyle intervention or treatment with metformin according to local label.
* Treatment with metformin should be stable (same dose and dosing frequency) for at least 56 days before screening.

Key exclusion criteria:

* Treatment with any medication prescribed for obesity or weight management within 90 days before screening.
* Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed:
* Liposuction and/or abdominoplasty, if performed \> 1 year before screening.
* Adjustable gastric banding, if the band has been removed \> 1 year before screening.
* Intragastric balloon, if the balloon has been removed \> 1 year before screening.
* Duodenal-jejunal bypass liner (e.g., Endobarrier), if the sleeve has been removed \>1 year before screening.
* Uncontrolled thyroid disease.
* Endocrine, hypothalamic, or syndromic obesity.
* A self-reported (or by parent(s)/LAR, where applicable) change in body weight \> 5 % within 90 days before screening irrespective of medical records.
* Type 1 diabetes or monogenic diabetes. For participants without T2D at screening the following exclusion criteria also apply
* HbA1c greater than or equal to 6.5% (48 mmol/mol) as measured by the central laboratory at screening.
* Treatment with glucose-lowering agent(s) prescribed for the indication of diabetes or pre-diabetes within 90 days before screening.

For participants with T2D at screening the following exclusion criteria also apply

* Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire.
* Recurrent severe hypoglycaemic episodes within 1 year before screening, as judged by the investigator.
* Positive insulinoma associated protein-2 (IA-2) antibodies or anti-glutamic acid decarboxylase (anti-GAD) antibodies.
* Treatment with any medication for the indication of diabetes other than those stated in the inclusion criteria within 90 days before screening.
* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

What this study is about

In the sponsor’s own words, from the registry.

This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to adolescents and adults) or placebo (a placebo looks like the treatment being tested, but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants who get semaglutide in the main study will not take part in the extension study. If participants take part in the extension study, they will get either CagriSema or cagrilintide in this part of the study. Like all drugs, the study drugs may have side effects. The total time participants will be in the main study is about 1 year and 6 months. If participants take part in the extension study, the total time is about 4 years and 10 months.

What participants receive

  • Experimental

    CagriSema

    Participants will receive once weekly subcutaneous (s.c.) dose of CagriSema (cagrilintide and semaglutide) in a dose escalation regimen in the main phase for up to 16 weeks and maintained for 52 weeks and further continue to receive the same dose or maximum tolerated dose (MTD) in the open-label extension phase for up to 156 weeks.

    Drug: Cagrilintide · Drug: Semaglutide · Drug: Placebo cagrilintide · Drug: Placebo semaglutide

  • Experimental

    Semaglutide

    Participants will receive once weekly s.c. dose of semaglutide in a dose escalation regimen in the main phase for up to 16 weeks and maintained for 52 weeks.

    Drug: Semaglutide · Drug: Placebo semaglutide

  • Experimental

    Cagrilintide

    Participants will receive once weekly s.c. dose of cagrilintide in a dose escalation regimen in the main phase for up to 16 weeks and maintained for 52 weeks, further continue to receive the same dose as the dose escalation regimen or MTD in the open-label extension phase for up to 156 weeks.

    Drug: Cagrilintide · Drug: Placebo cagrilintide

  • Placebo comparator

    Placebo

    Participants will receive once weekly s.c. dose of placebo matched to cagrilintide/semaglutide in a dose escalation regimen in the main phase for up to 16 weeks and maintained for 52 weeks. Participants will further continue to receive the same dose escalation regimen as CagriSema for 16 weeks, later continue to receive the same dose or MTD in the open-label extension phase for up to 140 weeks.

    Drug: Placebo cagrilintide · Drug: Placebo semaglutide

Interventions

  • CagrilintideDrug

    Participants will receive cagrilintide subcutaneously.

  • SemaglutideDrug

    Participants will receive semaglutide subcutaneously.

  • Placebo cagrilintideDrug

    Participants will receive placebo matched to cagrilintide subcutaneously.

  • Placebo semaglutideDrug

    Participants will receive placebo matched to semaglutide subcutaneously.

What the study measures

Primary outcomes

  1. Relative change in body mass index (BMI)

    Measured in percentage (%).

    Time frame: Baseline (week 0), week 68

Secondary outcomes

  1. Relative change in body weight

    Measured in %.

    Time frame: Baseline (week 0), week 68

  2. Change in BMI Standard Deviation Score (SDS)

    Measured as SDS score.

    Time frame: Baseline (week 0), week 68

  3. Relative change in BMI

    Measured in %.

    Time frame: Baseline (week 0), week 68 and week 224

  4. Number of participants in weight category reduction

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  5. Number of participants who achieved greater than or equal to (>=) 5 percent (%) reduction of body weight (yes/no)

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  6. Number of participants who achieved >=10% reduction of body weight (yes/no)

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  7. Number of participants who achieved >=15% reduction of body weight (yes/no)

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  8. Number of participants who achieved >=20% reduction of body weight (yes/no)

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  9. Number of participants who achieved >=25% reduction of body weight (yes/no)

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  10. Number of participants who achieved >=5% reduction of BMI (yes/no)

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  11. Number of participants who achieved >=10% reduction of BMI (yes/no)

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  12. Number of participants who achieved >=15% reduction of BMI (yes/no)

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  13. Number of participants who achieved >=20% reduction of BMI (yes/no)

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  14. Number of participants who achieved >=25% reduction of BMI (yes/no)

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  15. Number of participants who achieved normal BMI

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  16. Number of participants who shifted from obese to non-obese BMI class

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  17. Change in waist circumference

    Measured in centimeter (cm).

    Time frame: Baseline (week 0), week 68 and week 224

  18. Change in waist-to-height ratio

    Measured as ratio.

    Time frame: Baseline (week 0), week 68

  19. Absolute change in total fat mass by dual energy X-ray absorption (DXA)

    Measured in kilograms (kg).

    Time frame: Baseline (week 0), week 68

  20. Relative to baseline change in total fat mass by DXA

    Measured in %.

    Time frame: Baseline (week 0), week 68

  21. Relative to total body mass change in total fat mass by DXA

    Measured in % points.

    Time frame: Baseline (week 0), week 68

  22. Absolute change in visceral fat mass by DXA

    Measured in kg.

    Time frame: Baseline (week 0), week 68

  23. Relative to baseline change in visceral fat mass by DXA

    Measured in %.

    Time frame: Baseline (week 0), week 68

  24. Relative to total body mass change in visceral fat mass by DXA

    Measured in % points.

    Time frame: Baseline (week 0), week 68

  25. Absolute change in lean body mass by DXA

    Measured in kg.

    Time frame: Baseline (week 0), week 68

  26. Relative to total body mass change in lean body mass by DXA

    Measured in % points.

    Time frame: Baseline (week 0), week 68

  27. Absolute change in total (neck-to-knee) muscle and fat volumes by Magnetic Resonance Imaging (MRI) - total muscle and total fat

    Measured in liters (L).

    Time frame: Baseline (week 0), week 68 and week 224

  28. Relative to baseline change in total (neck-to-knee) muscle and fat volumes by MRI - total muscle and total fat

    Measured in %.

    Time frame: Baseline (week 0), week 68 and week 224

  29. Change in ectopic fat content by MRI - liver fat MRI-Proton Density Fat Fraction (MRI-PDFF), pancreatic fat, kidney fat and thigh muscle fat infiltration

    Measured in % points.

    Time frame: Baseline (week 0), week 68 and week 224

  30. Absolute change in abdominal fat volumes by MRI - subcutaneous fat and visceral fat

    Measured in liters.

    Time frame: Baseline (week 0), week 68 and week 224

  31. Relative to baseline change in abdominal fat volumes by MRI - subcutaneous fat and visceral fat

    Measured in %.

    Time frame: Baseline (week 0), week 68 and week 224

  32. Absolute change in thigh muscle and fat volumes by MRI - thigh fat free muscle and thigh subcutaneous fat

    Measured in liters.

    Time frame: Baseline (week 0), week 68 and week 224

  33. Relative to baseline change in thigh muscle and fat volumes by MRI - thigh fat free muscle and thigh subcutaneous fat

    Measured in %.

    Time frame: Baseline (week 0), week 68 and week 224

  34. Ratio to baseline in liver stiffness measured by Magnetic Resonance Elastography (MRE)

    Measured as ratio.

    Time frame: Baseline (week 0), week 68 and week 224

  35. Change in BMI percentage of the 95th percentile

    Measured in % points.

    Time frame: Baseline (week 0), week 68

  36. Ratio to baseline highly sensitive C-reactive protein (hs-CRP)

    Measured as ratio.

    Time frame: Baseline (week 0), week 68

  37. Ratio to baseline in lipids: Total cholesterol

    Measured as ratio.

    Time frame: Baseline (week 0), week 68 and week 224

  38. Ratio to baseline in lipids: High Density Lipoprotein (HDL) cholesterol

    Measured as ratio.

    Time frame: Baseline (week 0), week 68 and week 224

  39. Ratio to baseline in lipids: Low Density Lipoprotein (LDL) cholesterol

    Measured as ratio.

    Time frame: Baseline (week 0), week 68 and week 224

  40. Ratio to baseline in lipids: Very Low Density Lipoprotein (VLDL) cholesterol

    Measured as ratio.

    Time frame: Baseline (week 0), week 68 and week 224

  41. Ratio to baseline in lipids: Triglycerides

    Measured as ratio.

    Time frame: Baseline (week 0), week 68 and week 224

  42. Ratio to baseline in lipids: Non-HDL cholesterol

    Measured as ratio.

    Time frame: Baseline (week 0), week 68 and week 224

  43. Change in Alanine Transaminase (ALT)

    Measured in Units per Liter (U/L).

    Time frame: Baseline (week 0), week 68 and week 224

  44. Change in systolic blood pressure

    Measured in millimeters of mercury (mmHg).

    Time frame: Baseline (week 0), week 68 and week 224

  45. Change in diastolic blood pressure

    Measured in mmHg.

    Time frame: Baseline (week 0), week 68 and week 224

  46. Ratio to baseline in liver stiffness measured by ultrasonographic methods

    Measured as ratio.

    Time frame: Baseline (week 0), week 68 and week 224

  47. Change in glycated haemoglobin (HbA1c) (% points)

    Measured in % points.

    Time frame: Baseline (week 0), week 68 and week 224

  48. Change in HbA1c (millimoles per mole [mmol/mol])

    Measured in mmol/mol.

    Time frame: Baseline (week 0), week 68 and week 224

  49. Change in Fasting Plasma Glucose (FPG) (millimoles per liter [mmol/L])

    Measured in mmol/L.

    Time frame: Baseline (week 0), week 68

  50. Change in FPG (milligrams per deciliter [mg/dL])

    Measured in mg/dL.

    Time frame: Baseline (week 0), week 68

  51. Ratio to baseline in fasting serum insulin

    Measured as ratio.

    Time frame: Baseline (week 0), week 68 and week 224

  52. Number of participants with prediabetes who achieved HbA1c less than (<) 5.7% (defined as 5.7 % less than or equal to [<=] HbA1c <6.5 %) at baseline

    Measured as count of participants.

    Time frame: At week 68

  53. Number of participants with normoglycemia (defined as HbA1c < 5.7 %) at baseline, development of HbA1c greater than or equal to (>=) 5.7 %

    Measured as count of participants.

    Time frame: At week 68

  54. Number of participants with prediabetes (5.7 % <= HbA1c < 6.5 %) at baseline, development of HbA1c >= 6.5%

    Measured as count of participants.

    Time frame: At week 68

  55. Number of participants with HbA1c >=6.5% at baseline, achievement of HbA1c <6.5%

    Measured as count of participants.

    Time frame: At week 68

  56. Number of participants taking glucose lowering medication at baseline, stop or decrease

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  57. Number of participants taking antihypertensive medication at baseline, stop or decrease

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  58. Number of participants taking lipid lowering medication at baseline, stop or decrease

    Measured as count of participants.

    Time frame: Baseline (week 0), week 68

  59. Impact of Weight on Quality of Life-Kids (IWQOL Kids) - Physical comfort domain score

    Measured as score points. IWQOL-Kids measures weight-related quality of life in adolescents (ages 11-19 years) but will be administered to all study participants. The measure consists of 27-items yielding 4 sub-scale scores, and 1 total score. Higher scores indicate better weight-related quality of life. Subscale scores (score range): physical comfort (0-100), body esteem (0-100), social life (0-100), family relations (0-100) and total score (0-100).

    Time frame: Baseline (week 0), week 68 and week 224

  60. IWQOL Kids - Body esteem domain score

    Measured as score points. IWQOL-Kids measures weight-related quality of life in adolescents (ages 11-19 years) but will be administered to all study participants. The measure consists of 27-items yielding 4 sub-scale scores, and 1 total score. Higher scores indicate better weight-related quality of life. Subscale scores (score range): physical comfort (0-100), body esteem (0-100), social life (0-100), family relations (0-100) and total score (0-100).

    Time frame: Baseline (week 0), week 68 and week 224

  61. IWQOL Kids - Social life domain score

    Measured as score points. IWQOL-Kids measures weight-related quality of life in adolescents (ages 11-19 years) but will be administered to all study participants. The measure consists of 27-items yielding 4 sub-scale scores, and 1 total score. Higher scores indicate better weight-related quality of life. Subscale scores (score range): physical comfort (0-100), body esteem (0-100), social life (0-100), family relations (0-100) and total score (0-100).

    Time frame: Baseline (week 0), week 68 and week 224

  62. IWQOL Kids - Family-relations score

    Measured as score points. IWQOL-Kids measures weight-related quality of life in adolescents (ages 11-19 years) but will be administered to all study participants. The measure consists of 27-items yielding 4 sub-scale scores, and 1 total score. Higher scores indicate better weight-related quality of life. Subscale scores (score range): physical comfort (0-100), body esteem (0-100), social life (0-100), family relations (0-100) and total score (0-100).

    Time frame: Baseline (week 0), week 68 and week 224

  63. IWQOL Kids - Total score

    Measured as score points. IWQOL-Kids measures weight-related quality of life in adolescents (ages 11-19 years) but will be administered to all study participants. The measure consists of 27-items yielding 4 sub-scale scores, and 1 total score. Higher scores indicate better weight-related quality of life. Subscale scores (score range): physical comfort (0-100), body esteem (0-100), social life (0-100), family relations (0-100) and total score (0-100).

    Time frame: Baseline (week 0), week 68 and week 224

  64. Control of Eating Questionnaire (COEQ)

    Measured as score points. CoEQ is a 19-item multidimensional patient reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving control subscale, the subscale score is reversed so that a higher score represents a greater level of craving control.

    Time frame: Baseline (week 0), week 68 and week 224

  65. Change in proteomics-based serum biomarkers including biomarkers for metabolic dysfunction-associated steatohepatitis (MASH)

    Measured as counts.

    Time frame: Baseline (week 0), week 68 and week 224

  66. Number of treatment-emergent adverse events (TEAEs)

    Measured as count of events.

    Time frame: Baseline (week 0), week 68 and week 224

  67. Number of treatment-emergent serious adverse events (TESAEs)

    Measured as count of events.

    Time frame: Baseline (week 0), week 68 and week 224

  68. Number of treatment-emergent hypoglycaemic episodes

    Measured as count of events.

    Time frame: Baseline (week 0), week 68 and week 224

  69. Change in pulse rate

    Measured in beats per minute (beats/min).

    Time frame: Baseline (week 0), week 68

  70. Change in calcitonin

    Measured in nanograms per liter (ng/L).

    Time frame: Baseline (week 0), week 68

  71. Apparent clearance (CL/F) of semaglutide and cagrilintide at steady state

    Measured in liters per hour (L/h).

    Time frame: Baseline (week 0), week 68

  72. Average concentration (Cavg) of semaglutide and cagrilintide at steady state

    Measured in nanomoles per liter (nmol/L).

    Time frame: Baseline (week 0), week 68

  73. Area under the steady-state concentration-time curves (AUCt) in the dosing interval of semaglutide and cagrilintide

    Measured in hours nanomoles per liter (h·nmol/L).

    Time frame: Baseline (week 0), week 68

Who is running it

Lead sponsor
Novo Nordisk A/S
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Novo Nordisk A/S
Data monitoring committee
No
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
NN9838-4968
Other IDs
U1111-1299-4751, 2023-509176-42, 2023

  • Clinical Transparency (dept. 2834)

    Study director

    Novo Nordisk A/S

Study sites(121)

  • Endolife Specialty Hospitals

    Guntur, Andhra Pradesh, India

    Not yet recruiting

  • BAPS Pramukh Swami Hospital

    Surat, Gujarat, India

    Not yet recruiting

  • Indira Gandhi Institute of child health

    Bangalore, Karnataka, India

    Not yet recruiting

  • Sir Ganga Ram Hospital

    New Delhi, National Capital Territory of Delhi, India

    Not yet recruiting

  • Maulana Azad Medical College

    Delhi, New Delhi, India

    Not yet recruiting

  • Regency Hospital

    Kanpur, Uttar Pradesh, India

    Not yet recruiting

  • Institute of Child Health

    Kolkata, West Bengal, India

    Not yet recruiting

  • Excel Endocrine Centre

    Kolhāpur, India

    Not yet recruiting

  • All India Institute of Medical Sciences (AIIMS)

    New Delhi, India

    Not yet recruiting

  • Neighborhood Healthcare

    Escondido, California, United States

    Recruiting

  • Encore Medical Research LLC

    Hollywood, Florida, United States

    Recruiting

  • Jacksonville Ctr for Clin Res

    Jacksonville, Florida, United States

    Recruiting

  • Encore Medical Research of Weston

    Weston, Florida, United States

    Recruiting

  • Children's Healthcare Atlanta

    Atlanta, Georgia, United States

    Recruiting

  • Columbus Research Foundation

    Columbus, Georgia, United States

    Recruiting

  • Accel Research Sites-NeuroStudies

    Decatur, Georgia, United States

    Recruiting

  • Eastside Bariatric and Gen Surg

    Snellville, Georgia, United States

    Recruiting

  • Solaris Clinical Research

    Meridian, Idaho, United States

    Recruiting

  • IU Health - Riley Physicians Endo-Diab

    Indianapolis, Indiana, United States

    Recruiting

  • Cotton O'Neil Clinical Research Center

    Topeka, Kansas, United States

    Recruiting

  • Pennington Biomed Res Ctr

    Baton Rouge, Louisiana, United States

    Recruiting

  • Barry J. Reiner, MD LLC

    Baltimore, Maryland, United States

    Recruiting

  • University of Minnesota

    Minneapolis, Minnesota, United States

    Recruiting

  • Synexus Clinical Research US-MN

    Richfield, Minnesota, United States

    Recruiting

  • SUNY Upstate Medical Univ - Syracuse

    Syracuse, New York, United States

    Recruiting

  • Valley Weight Loss Clinic

    Fargo, North Dakota, United States

    Recruiting

  • Centricity Research - Ohio

    Columbus, Ohio, United States

    Recruiting

  • PriMed Clinical Research

    Dayton, Ohio, United States

    Recruiting

  • Coastal Carolina Research Ctr

    North Charleston, South Carolina, United States

    Recruiting

  • LifeDoc Health

    Memphis, Tennessee, United States

    Recruiting

  • DM Clinical

    Houston, Texas, United States

    Recruiting

  • The Texas Liver Institute

    San Antonio, Texas, United States

    Recruiting

  • Pinnacle Clinical Research

    San Antonio, Texas, United States

    Recruiting

  • Consano Clin Res-Shavano Park

    Shavano Park, Texas, United States

    Recruiting

  • Texas Valley Clinical Research

    Weslaco, Texas, United States

    Recruiting

  • AMR Clinical

    Layton, Utah, United States

    Recruiting

  • The Children's Hospital at Westmead - Clinical Research Centre

    Westmead, New South Wales, Australia

    Recruiting

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia

    Recruiting

  • Perth Children's Hospital

    Nedlands, Western Australia, Australia

    Recruiting

  • Universitätsklinik Kinder-Jugendheilkunde Innsbruck

    Innsbruck, Austria

    Recruiting

Showing 40 of 121 sites, filter to narrow it down. 65 of 121 on this study are recruiting right now, and 9 are in India. A site can stop enrolling while the study as a whole is still open.

References and data sharing

Participant data shared
Yes

According to the Novo Nordisk disclosure commitment on NovoNordisk trials.com.

Source: ClinicalTrials.gov record NCT07253285, status verified September 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.

Back to the catalogue
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weig | Trialion